Public Profile

Basilea Pharmaceutica

Basilea Pharmaceutica AG, commonly referred to as Basilea, is a Swiss biopharmaceutical company headquartered in Basel, Switzerland. Founded in 2000, Basilea focuses on the development and commercialisation of innovative therapies for oncology and infectious diseases. The company has made significant strides in the pharmaceutical industry, particularly with its core products, which include advanced treatments for resistant infections and cancer. Basilea's unique approach combines cutting-edge research with a commitment to addressing unmet medical needs, positioning it as a key player in the global biopharmaceutical landscape. With a strong presence in Europe and North America, Basilea has achieved notable milestones, including successful product launches and strategic partnerships that enhance its market position. The company's dedication to innovation and patient care continues to drive its growth and reputation in the industry.

DitchCarbon Score

How does Basilea Pharmaceutica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

6

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

6

Industry Benchmark

Basilea Pharmaceutica's score of 6 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

1%

Basilea Pharmaceutica's reported carbon emissions

Basilea Pharmaceutica, headquartered in Switzerland (CH), currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current carbon footprint or climate strategy. However, as a company in the pharmaceutical industry, Basilea is likely to be aware of the increasing importance of sustainability and may be exploring avenues to enhance their environmental performance in line with industry standards. Further information on their climate commitments or future initiatives may be forthcoming as they develop their sustainability strategies.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Basilea Pharmaceutica's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Basilea Pharmaceutica is headquartered in CH, which has a rank of very low, indicating very low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Basilea Pharmaceutica is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Other Organizations in Health Services

GrowEx

BD
Health Services
Updated 11 days ago

Jazz Pharmaceuticals

GB
Health Services
Updated 10 days ago

Clinica Esperanza De Triana S.A.

ES
Health Services
Updated 2 days ago

Optima Health

GB
Health Services
Updated 8 days ago

IDEXX Laboratories, KK

JP
Health Services
Updated 2 days ago

Cryopak

CA
Health Services
Updated 11 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers